Bridging Use of Plasma Exchange and Continuous Hemodiafiltration before Living Donor Liver Transplantation in Fulminant Wilson's Disease

Yoshiko Nagata, Hirofumi Uto, Satoru Hasuike, Akio Ido, Katsuhiro Hayashi, Toshiharu Eto, Toshiro Hamakawa, Kōichi Tanaka, Hirohito TsubouchiInternal 2003 · DOI

Abstract

A 15-year-old girl presented with acute hepatic failure showing ascites and hepatic encephalopathy, accompanied by hemolytic anemia. She was diagnosed as having fulminant Wilson's disease (FWD). Plasma exchange (PE), continuous hemodiafiltration (CHDF) and D-penicillamine administration were started immediately. Copper [24,000 μg] was removed by PE and CHDF over three days, which relieved the jaundice and the consciousness disorder. A successful liver transplant followed. FWD progresses rapidly and often liver transplantation is the only possible therapy. In this case, PE and CHDF were an effective therapy bridge until liver transplantation.

Introduction

Wilson’s disease is a rare autosomal recessive disorder characterized by impaired copper transport and excretion, leading to toxic accumulation in various organs, primarily the liver and brain. While many patients are managed with lifelong chelation therapy, a subset develops Fulminant Wilson’s Disease (FWD), a catastrophic presentation of acute-on-chronic liver failure. FWD is often accompanied by Coombs-negative hemolytic anemia and renal failure, carrying a near 100% mortality rate without urgent liver transplantation. However, patients are frequently too unstable for immediate surgery. This case report explores the use of combined Plasma Exchange (PE) and Continuous Hemodiafiltration (CHDF) as a quantitative "bridge" to stabilize a patient for living donor liver transplantation (LDLT).

Case Presentation

A 15-year-old girl was admitted with sudden-onset jaundice, ascites, and hepatic encephalopathy. Laboratory evaluation revealed severe anemia (Hb 4.9 g/dl), massive hyperbilirubinemia (Total Bilirubin 46.0 mg/dl), and significant coagulopathy (PT 13.4%).

Initial laboratory findings on admission, showing severe anemia, jaundice, and coagulopathy.

Diagnostic hallmarks of FWD were present, including a low alkaline phosphatase (ALP) relative to bilirubin and an AST level significantly higher than ALT. The diagnosis was confirmed by a markedly elevated urinary copper excretion (4,987 μg/day) and low ceruloplasmin levels.

Clinical Intervention and Quantitative Copper Removal

To stabilize the patient, a multi-modal apheresis strategy was initiated:

  1. Plasma Exchange (PE): Aimed at removing protein-bound copper and replacing deficient coagulation factors.
  2. Continuous Hemodiafiltration (CHDF): Implemented to filter "free" (unbound) copper and metabolic waste while managing fluid balance and protecting renal function.
  3. Chelation Therapy: D-penicillamine was administered to help mobilize tissue copper into the circulation for removal.

The efficiency of these methods was quantitatively monitored by measuring copper concentrations in the discarded plasma and dialysate.

Quantitative assessment of copper removal by plasma exchange (PE) and continuous hemodiafiltration (CHDF) over the first three days.

Over 72 hours, the combination therapy removed approximately 24,000 μg of copper. PE served as the primary mechanism for removal (approx. 20,600 μg), while CHDF contributed significantly (approx. 3,400 μg) and provided essential renal support.

Results and Outcome

The intensive detoxification led to rapid clinical improvement. Serum copper levels decreased from 253 μg/dl to 126 μg/dl. Hepatic encephalopathy resolved, and jaundice improved significantly, with total bilirubin dropping to 18.1 mg/dl. This stabilization allowed the patient to undergo a successful LDLT from her father 11 days after admission. Histological analysis of the explanted liver confirmed underlying cirrhosis and massive copper deposition. The patient was discharged in good health six weeks post-transplant.

Discussion

The management of FWD requires rapid reduction of the systemic copper load to prevent further multi-organ failure. This case demonstrates that while PE is highly effective at removing protein-bound copper, the addition of CHDF is crucial for managing the "free" copper fraction that drives hemolysis and for providing renal replacement therapy. The quantitative data provided here underscores the synergistic effect of these modalities.

While effective, these therapies are temporary measures. The underlying liver pathology in FWD is typically irreversible cirrhosis, making transplantation the only definitive cure. The use of PE and CHDF should be viewed as a vital "bridge" to optimize the patient's physiological state before high-risk surgery.

Conclusion

Combined PE and CHDF, alongside chelation therapy, is an effective strategy for the rapid detoxification of patients with Fulminant Wilson’s Disease. By quantifying copper removal, this case provides evidence for the efficacy of this approach in stabilizing critically ill patients, thereby serving as a successful bridge to life-saving liver transplantation.

Summary updated

Abstract

A 15-year-old girl presented with acute hepatic failure showing ascites and hepatic encephalopathy, accompanied by hemolytic anemia. She was diagnosed as having fulminant Wilson's disease (FWD). Plasma exchange (PE), continuous hemodiafiltration (CHDF) and D-penicillamine administration were started immediately. Copper [24,000 microg] was removed by PE and CHDF over three days, which relieved the jaundice and the consciousness disorder. A successful liver transplant followed. FWD progresses rapidly and often liver transplantation is the only possible therapy. In this case, PE and CHDF were an effective therapy bridge until liver transplantation.
BibTeX
@inproceedings{nagata2003bridging,
  author = {Yoshiko Nagata and Hirofumi Uto and Satoru Hasuike and Akio Ido and Katsuhiro Hayashi and Toshiharu Eto and Toshiro Hamakawa and Kōichi Tanaka and Hirohito Tsubouchi},
  title = {{Bridging Use of Plasma Exchange and Continuous Hemodiafiltration before Living Donor Liver Transplantation in Fulminant Wilson's Disease}},
  booktitle = {Internal},
  year = {2003},
  doi = {10.2169/internalmedicine.42.967},
}
Figure